Pfizer withdraws adalimumab biosimilar from EMA.

Pfizer has in a letter to the EMA stated that it seeks to the withdraw its adalimumab biosimilar now called Fyzoclad , explaining that its decision was due to a change in the company�s strategy. The first biosimilars of adalimumab appeared on the European market in October 2018. Stronger patent protections in the U.S.have allowed AbbVie to negotiate settlements with several biosimilar drugmakers delaying launch of these products in the U.S until 2023